Race against time: new stroke drug trial aims to save more brain function
NCT ID NCT06658197
Summary
This large Phase 3 trial is testing which of two clot-busting drugs works better for people having a major stroke caused by a large blocked artery. About 850 patients will be randomly assigned to receive either the standard drug (alteplase) or a newer alternative (tenecteplase) within 4.5 hours of stroke symptoms, followed by a procedure to physically remove the clot. The main goal is to see which drug combination helps more people regain independence in daily life 90 days after their stroke.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STROKE, ACUTE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Xuanwu Hospital, Capital Medical University
RECRUITINGBeijing, Beijing Municipality, 100053, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.